SMIM1_HUMAN
ID SMIM1_HUMAN Reviewed; 78 AA.
AC B2RUZ4;
DT 16-DEC-2008, integrated into UniProtKB/Swiss-Prot.
DT 01-JUL-2008, sequence version 1.
DT 03-AUG-2022, entry version 93.
DE RecName: Full=Small integral membrane protein 1 {ECO:0000303|PubMed:23505126, ECO:0000312|HGNC:HGNC:44204};
DE AltName: Full=Vel blood group antigen {ECO:0000303|PubMed:23505126};
GN Name=SMIM1 {ECO:0000303|PubMed:23505126, ECO:0000312|HGNC:HGNC:44204};
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16710414; DOI=10.1038/nature04727;
RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT "The DNA sequence and biological annotation of human chromosome 1.";
RL Nature 441:315-321(2006).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [3]
RP PROTEIN SEQUENCE OF 1-10 AND 43-52, IDENTIFICATION BY MASS SPECTROMETRY,
RP POLYMORPHISM, SUBUNIT, AND DISULFIDE BOND.
RX PubMed=23505126; DOI=10.1002/emmm.201302466;
RA Ballif B.A., Helias V., Peyrard T., Menanteau C., Saison C., Lucien N.,
RA Bourgouin S., Le Gall M., Cartron J.P., Arnaud L.;
RT "Disruption of SMIM1 causes the Vel- blood type.";
RL EMBO Mol. Med. 5:751-761(2013).
RN [4]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22 AND SER-27, AND
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA Elledge S.J., Gygi S.P.;
RT "A quantitative atlas of mitotic phosphorylation.";
RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN [5]
RP POLYMORPHISM, SUBUNIT, DISULFIDE BOND, TISSUE SPECIFICITY, AND TOPOLOGY.
RX PubMed=23563606; DOI=10.1038/ng.2600;
RA Storry J.R., Joud M., Christophersen M.K., Thuresson B., Akerstrom B.,
RA Sojka B.N., Nilsson B., Olsson M.L.;
RT "Homozygosity for a null allele of SMIM1 defines the Vel-negative blood
RT group phenotype.";
RL Nat. Genet. 45:537-541(2013).
RN [6]
RP POLYMORPHISM, VARIANTS LYS-51 AND ARG-51, AND CHARACTERIZATION OF VARIANTS
RP LYS-51 AND ARG-51.
RX PubMed=23563608; DOI=10.1038/ng.2603;
RA Cvejic A., Haer-Wigman L., Stephens J.C., Kostadima M., Smethurst P.A.,
RA Frontini M., van den Akker E., Bertone P., Bielczyk-Maczynska E.,
RA Farrow S., Fehrmann R.S., Gray A., de Haas M., Haver V.G., Jordan G.,
RA Karjalainen J., Kerstens H.H., Kiddle G., Lloyd-Jones H., Needs M.,
RA Poole J., Soussan A.A., Rendon A., Rieneck K., Sambrook J.G., Schepers H.,
RA Sillje H.H., Sipos B., Swinkels D., Tamuri A.U., Verweij N., Watkins N.A.,
RA Westra H.J., Stemple D., Franke L., Soranzo N., Stunnenberg H.G.,
RA Goldman N., van der Harst P., van der Schoot C.E., Ouwehand W.H.,
RA Albers C.A.;
RT "SMIM1 underlies the Vel blood group and influences red blood cell
RT traits.";
RL Nat. Genet. 45:542-545(2013).
RN [7]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-22, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Liver;
RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA Ye M., Zou H.;
RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT phosphoproteome.";
RL J. Proteomics 96:253-262(2014).
RN [8]
RP PHOSPHORYLATION AT SER-6; SER-17; SER-22 AND SER-27, SUBCELLULAR LOCATION,
RP TOPOLOGY, MUTAGENESIS OF SER-6; SER-17; SER-22; SER-27; CYS-35; CYS-43 AND
RP 76-LYS--LYS-78, DOMAIN, REGION, ACETYLATION AT MET-1, AND IDENTIFICATION BY
RP MASS SPECTROMETRY.
RX PubMed=26452714; DOI=10.1016/j.febslet.2015.09.029;
RA Arnaud L., Kelley L.P., Helias V., Cartron J.P., Ballif B.A.;
RT "SMIM1 is a type II transmembrane phosphoprotein and displays the Vel blood
RT group antigen at its carboxyl-terminus.";
RL FEBS Lett. 589:3624-3630(2015).
CC -!- FUNCTION: Regulator of red blood cell formation.
CC {ECO:0000250|UniProtKB:B3DHH5}.
CC -!- SUBUNIT: Homooligomer; disulfide-linked. {ECO:0000269|PubMed:23505126,
CC ECO:0000269|PubMed:23563606}.
CC -!- INTERACTION:
CC B2RUZ4; Q68DC2: ANKS6; NbExp=3; IntAct=EBI-12188413, EBI-7054139;
CC B2RUZ4; Q13520: AQP6; NbExp=3; IntAct=EBI-12188413, EBI-13059134;
CC B2RUZ4; Q8WWH4: ASZ1; NbExp=3; IntAct=EBI-12188413, EBI-12239061;
CC B2RUZ4; Q9BXK5: BCL2L13; NbExp=3; IntAct=EBI-12188413, EBI-747430;
CC B2RUZ4; Q13323: BIK; NbExp=3; IntAct=EBI-12188413, EBI-700794;
CC B2RUZ4; P04233-2: CD74; NbExp=3; IntAct=EBI-12188413, EBI-12222807;
CC B2RUZ4; Q8N5K1: CISD2; NbExp=3; IntAct=EBI-12188413, EBI-1045797;
CC B2RUZ4; P21964: COMT; NbExp=3; IntAct=EBI-12188413, EBI-372265;
CC B2RUZ4; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-12188413, EBI-6942903;
CC B2RUZ4; P49447: CYB561; NbExp=3; IntAct=EBI-12188413, EBI-8646596;
CC B2RUZ4; Q15125: EBP; NbExp=3; IntAct=EBI-12188413, EBI-3915253;
CC B2RUZ4; Q9Y282: ERGIC3; NbExp=3; IntAct=EBI-12188413, EBI-781551;
CC B2RUZ4; Q8TBP5: FAM174A; NbExp=3; IntAct=EBI-12188413, EBI-18636064;
CC B2RUZ4; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-12188413, EBI-18304435;
CC B2RUZ4; Q96KR6: FAM210B; NbExp=3; IntAct=EBI-12188413, EBI-18938272;
CC B2RUZ4; O15552: FFAR2; NbExp=3; IntAct=EBI-12188413, EBI-2833872;
CC B2RUZ4; Q8TBE3: FNDC9; NbExp=3; IntAct=EBI-12188413, EBI-12142257;
CC B2RUZ4; P48165: GJA8; NbExp=3; IntAct=EBI-12188413, EBI-17458373;
CC B2RUZ4; O95377: GJB5; NbExp=3; IntAct=EBI-12188413, EBI-3909454;
CC B2RUZ4; Q6Y1H2: HACD2; NbExp=3; IntAct=EBI-12188413, EBI-530257;
CC B2RUZ4; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-12188413, EBI-18053395;
CC B2RUZ4; P32942: ICAM3; NbExp=3; IntAct=EBI-12188413, EBI-725421;
CC B2RUZ4; Q8N5M9: JAGN1; NbExp=3; IntAct=EBI-12188413, EBI-10266796;
CC B2RUZ4; P43628: KIR2DL3; NbExp=3; IntAct=EBI-12188413, EBI-8632435;
CC B2RUZ4; Q8TAF8: LHFPL5; NbExp=3; IntAct=EBI-12188413, EBI-2820517;
CC B2RUZ4; Q7Z4F1: LRP10; NbExp=3; IntAct=EBI-12188413, EBI-2830349;
CC B2RUZ4; Q9HCJ2: LRRC4C; NbExp=3; IntAct=EBI-12188413, EBI-3925442;
CC B2RUZ4; Q9GZY8-5: MFF; NbExp=3; IntAct=EBI-12188413, EBI-11956541;
CC B2RUZ4; Q6ZSS7: MFSD6; NbExp=3; IntAct=EBI-12188413, EBI-2858252;
CC B2RUZ4; P15941-11: MUC1; NbExp=3; IntAct=EBI-12188413, EBI-17263240;
CC B2RUZ4; Q9Y3Q0: NAALAD2; NbExp=3; IntAct=EBI-12188413, EBI-2863682;
CC B2RUZ4; Q8N183: NDUFAF2; NbExp=3; IntAct=EBI-12188413, EBI-2682365;
CC B2RUZ4; P15151: PVR; NbExp=3; IntAct=EBI-12188413, EBI-3919694;
CC B2RUZ4; Q9H6H4: REEP4; NbExp=3; IntAct=EBI-12188413, EBI-7545592;
CC B2RUZ4; Q8NC24: RELL2; NbExp=3; IntAct=EBI-12188413, EBI-10269209;
CC B2RUZ4; Q86VR2: RETREG3; NbExp=3; IntAct=EBI-12188413, EBI-10192441;
CC B2RUZ4; Q9NR31: SAR1A; NbExp=3; IntAct=EBI-12188413, EBI-3920694;
CC B2RUZ4; Q9NY72: SCN3B; NbExp=3; IntAct=EBI-12188413, EBI-17247926;
CC B2RUZ4; A0A0S2Z4U3: SDC3; NbExp=3; IntAct=EBI-12188413, EBI-10204280;
CC B2RUZ4; Q9Y286: SIGLEC7; NbExp=3; IntAct=EBI-12188413, EBI-2801178;
CC B2RUZ4; Q3KNW5: SLC10A6; NbExp=3; IntAct=EBI-12188413, EBI-18159983;
CC B2RUZ4; P54219-3: SLC18A1; NbExp=3; IntAct=EBI-12188413, EBI-17595455;
CC B2RUZ4; Q86WA9: SLC26A11; NbExp=3; IntAct=EBI-12188413, EBI-19115335;
CC B2RUZ4; Q86WV6: STING1; NbExp=3; IntAct=EBI-12188413, EBI-2800345;
CC B2RUZ4; Q16623: STX1A; NbExp=3; IntAct=EBI-12188413, EBI-712466;
CC B2RUZ4; Q96DZ7: TM4SF19; NbExp=3; IntAct=EBI-12188413, EBI-6448756;
CC B2RUZ4; Q6P9G4: TMEM154; NbExp=3; IntAct=EBI-12188413, EBI-13329239;
CC B2RUZ4; Q96B21: TMEM45B; NbExp=3; IntAct=EBI-12188413, EBI-3923061;
CC B2RUZ4; Q9NW97: TMEM51; NbExp=3; IntAct=EBI-12188413, EBI-726044;
CC B2RUZ4; Q4KMG9: TMEM52B; NbExp=3; IntAct=EBI-12188413, EBI-18178701;
CC B2RUZ4; Q8N661: TMEM86B; NbExp=3; IntAct=EBI-12188413, EBI-2548832;
CC B2RUZ4; O15393-2: TMPRSS2; NbExp=3; IntAct=EBI-12188413, EBI-12345267;
CC B2RUZ4; Q9Y320: TMX2; NbExp=3; IntAct=EBI-12188413, EBI-6447886;
CC B2RUZ4; Q96MV8: ZDHHC15; NbExp=3; IntAct=EBI-12188413, EBI-12837904;
CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26452714};
CC Single-pass type II membrane protein {ECO:0000269|PubMed:26452714}.
CC -!- TISSUE SPECIFICITY: Highly expressed in the bone marrow and expressed
CC at lower levels in non-hematopoietic tissues. Highly expressed in
CC erythroleukemia cell lines. Up-regulated in CD34+ hematopoietic
CC progenitors cultured toward red blood cells.
CC {ECO:0000269|PubMed:23563606}.
CC -!- DOMAIN: The extracellular domain carries the Vel antigen.
CC {ECO:0000269|PubMed:26452714}.
CC -!- POLYMORPHISM: SMIM1 is responsible for the Vel blood group system (VEL)
CC [MIM:615264]. The Vel antigen is present on red blood cells from all
CC people except rare Vel-negative individuals who can form antibodies to
CC Vel in response to transfusion or pregnancy. These antibodies may cause
CC severe hemolytic reactions in blood recipients. In most cases, Vel-
CC negative individuals are homozygous for a 17-nucleotide frameshift
CC deletion in exon 3. In some cases, Vel-negative are heterozygous for
CC the 17-nucleotide frameshift deletion and a missense variant at
CC position 51. {ECO:0000269|PubMed:23563608}.
CC -!- SIMILARITY: Belongs to the SMIM1 family. {ECO:0000305}.
CC -!- WEB RESOURCE: Name=Protein Spotlight; Note=Seeing red - Issue 184 of
CC October 2016;
CC URL="https://web.expasy.org/spotlight/back_issues/184/";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AL365330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC146945; -; NOT_ANNOTATED_CDS; mRNA.
DR EMBL; BC146957; -; NOT_ANNOTATED_CDS; mRNA.
DR CCDS; CCDS57966.1; -.
DR RefSeq; NP_001157196.1; NM_001163724.2.
DR RefSeq; NP_001275512.1; NM_001288583.1.
DR AlphaFoldDB; B2RUZ4; -.
DR SMR; B2RUZ4; -.
DR BioGRID; 132762; 58.
DR IntAct; B2RUZ4; 56.
DR STRING; 9606.ENSP00000457386; -.
DR TCDB; 1.A.124.1.1; the small mitochondrial integral membrane protein (smim) family.
DR iPTMnet; B2RUZ4; -.
DR PhosphoSitePlus; B2RUZ4; -.
DR SwissPalm; B2RUZ4; -.
DR BioMuta; SMIM1; -.
DR EPD; B2RUZ4; -.
DR jPOST; B2RUZ4; -.
DR MassIVE; B2RUZ4; -.
DR PaxDb; B2RUZ4; -.
DR PeptideAtlas; B2RUZ4; -.
DR PRIDE; B2RUZ4; -.
DR TopDownProteomics; B2RUZ4; -.
DR Antibodypedia; 74931; 36 antibodies from 9 providers.
DR DNASU; 388588; -.
DR Ensembl; ENST00000444870.7; ENSP00000457386.1; ENSG00000235169.11.
DR Ensembl; ENST00000642557.4; ENSP00000496314.2; ENSG00000235169.11.
DR GeneID; 388588; -.
DR KEGG; hsa:388588; -.
DR MANE-Select; ENST00000642557.4; ENSP00000496314.2; NM_001288583.2; NP_001275512.1.
DR CTD; 388588; -.
DR DisGeNET; 388588; -.
DR GeneCards; SMIM1; -.
DR HGNC; HGNC:44204; SMIM1.
DR HPA; ENSG00000235169; Tissue enhanced (bone marrow, testis).
DR MalaCards; SMIM1; -.
DR MIM; 615242; gene.
DR MIM; 615264; phenotype.
DR neXtProt; NX_B2RUZ4; -.
DR OpenTargets; ENSG00000235169; -.
DR VEuPathDB; HostDB:ENSG00000235169; -.
DR eggNOG; ENOG502SASD; Eukaryota.
DR GeneTree; ENSGT00520000060291; -.
DR HOGENOM; CLU_2621305_0_0_1; -.
DR InParanoid; B2RUZ4; -.
DR OMA; RWENSHP; -.
DR OrthoDB; 1629265at2759; -.
DR PhylomeDB; B2RUZ4; -.
DR PathwayCommons; B2RUZ4; -.
DR SignaLink; B2RUZ4; -.
DR BioGRID-ORCS; 388588; 12 hits in 1062 CRISPR screens.
DR Pharos; B2RUZ4; Tbio.
DR PRO; PR:B2RUZ4; -.
DR Proteomes; UP000005640; Chromosome 1.
DR RNAct; B2RUZ4; protein.
DR Bgee; ENSG00000235169; Expressed in right testis and 112 other tissues.
DR ExpressionAtlas; B2RUZ4; baseline and differential.
DR Genevisible; B2RUZ4; HS.
DR GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR InterPro; IPR031744; SMIM1.
DR PANTHER; PTHR38503; PTHR38503; 1.
DR Pfam; PF15875; DUF4731; 1.
PE 1: Evidence at protein level;
KW Acetylation; Blood group antigen; Cell membrane; Direct protein sequencing;
KW Disulfide bond; Membrane; Phosphoprotein; Reference proteome;
KW Signal-anchor; Transmembrane; Transmembrane helix.
FT CHAIN 1..78
FT /note="Small integral membrane protein 1"
FT /id="PRO_0000356182"
FT TOPO_DOM 1..46
FT /note="Cytoplasmic"
FT /evidence="ECO:0000269|PubMed:26452714"
FT TRANSMEM 47..67
FT /note="Helical; Signal-anchor for type II membrane protein"
FT /evidence="ECO:0000255"
FT TOPO_DOM 68..78
FT /note="Extracellular"
FT /evidence="ECO:0000269|PubMed:26452714"
FT REGION 1..20
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 68..78
FT /note="Displays the Vel antigen"
FT /evidence="ECO:0000269|PubMed:26452714"
FT MOD_RES 1
FT /note="N-acetylmethionine"
FT /evidence="ECO:0000269|PubMed:26452714"
FT MOD_RES 6
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:26452714"
FT MOD_RES 17
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:26452714"
FT MOD_RES 22
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:26452714,
FT ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:24275569"
FT MOD_RES 27
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:26452714,
FT ECO:0007744|PubMed:18669648"
FT VARIANT 51
FT /note="M -> K (found in Vel-negative population; unknown
FT pathological significance; heterozygous with the 17-
FT nucleotide frameshift deletion; dbSNP:rs1182690110)"
FT /evidence="ECO:0000269|PubMed:23563608"
FT /id="VAR_069360"
FT VARIANT 51
FT /note="M -> R (found in Vel-negative population; unknown
FT pathological significance; heterozygous with the 17-
FT nucleotide frameshift deletion)"
FT /evidence="ECO:0000269|PubMed:23563608"
FT /id="VAR_069361"
FT MUTAGEN 6
FT /note="S->A: No effect on cell membrane localization; when
FT associated with A-17; A-22 and A-27. No effect on cell
FT surface expression of the Vel antigen; when associated with
FT A-17; A-22 and A-27."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 17
FT /note="S->A: No effect on cell membrane localization; when
FT associated with A-6; A-22 and A-27. No effect on cell
FT surface expression of the Vel antigen; when associated with
FT A-6; A-22 and A-27."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 22
FT /note="S->A: No effect on cell membrane localization; when
FT associated with A-6; A-17 and A-27. No effect on cell
FT surface expression of the Vel antigen; when associated with
FT A-6; A-17 and A-27."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 27
FT /note="S->A: No effect on cell membrane localization; when
FT associated with A-6; A-17 and A-22. No effect on cell
FT surface expression of the Vel antigen; when associated with
FT A-6; A-17 and A-22."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 35
FT /note="C->S: No effect on cell surface expression of the
FT Vel antigen; when associated with S-43."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 43
FT /note="C->S: No effect on cell surface expression of the
FT Vel antigen; when associated with S-35."
FT /evidence="ECO:0000269|PubMed:26452714"
FT MUTAGEN 76..78
FT /note="Missing: Loss of cell-surface expression of the Vel
FT antigen."
FT /evidence="ECO:0000269|PubMed:26452714"
SQ SEQUENCE 78 AA; 8749 MW; 72B2879DC4986A82 CRC64;
MQPQESHVHY SRWEDGSRDG VSLGAVSSTE EASRCRRISQ RLCTGKLGIA MKVLGGVALF
WIIFILGYLT GYYVHKCK
